Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC has landed an investment from Houston-based Modi Ventures and named its founder, Sahir Ali (far left), to its board. Photo courtesy Rice University Biotech Launch Pad via LinkedIn

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

From Your Site Articles
Innovation Labs @ TMC will open next year at the TMC Innovation Factory. Photo courtesy JLABS.

Innovation Labs @ TMC set to launch for early-stage life science startups

moving in

The Texas Medical Center will launch its new Innovation Labs @ TMC in January 2026 to better support life science startups working within the innovation hub.

The 34,000-square-foot space, located in the TMC Innovation Factory at 2450 Holcombe Blvd., will feature labs and life science offices and will be managed by TMC. The space was previously occupied by Johnson & Johnson's JLABS @TMC, a representative from TMC tells InnovationMap. JLABS will officially vacate the space in January.

TMC shares that the expansion will allow it to "open its doors to a wider range of life science visionaries," including those in the TMC BioBridge program and Innovation Factory residents. It will also allow TMC to better integrate with the Innovation Factory's offerings, such as the TMC Health Tech accelerator, TMC Center for Device Innovation and TMC Venture Fund.

“We have witnessed an incredible demand for life science space, not only at the TMC Innovation Factory, but also on the TMC Helix Park research campus,” William McKeon, president and CEO of the TMC, said in a news release. “Innovation Labs @ TMC enables us to meet this rising demand and continue reshaping how early-stage life science companies grow, connect, and thrive.”

“By bringing together top talent, cutting-edge research, and industry access in one central hub, we can continue to advance Houston’s life science ecosystem," he continued.

The TMC Innovation Factory has hosted 450 early-stage ventures since it launched in 2015. JLABS first opened in the space in 2016 with the goal of helping health care startups commercialize.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Koda Health has raised funding to fuel growth of its digital advance care planning company. Image via kodahealthcare.com

Houston digital health platform raises additional seed funding from fresh investors

money moves

A Houston-born digital advance care planning company, has secured new funding from some big names.

Koda Health achieved a successful oversubscription of additional seed round funding thanks to the participation of AARP, Memorial Hermann Health System, and the Texas Medical Center Venture Fund. The total amount raised was undisclosed, and the round was led by Austin-based Ecliptic Capital.

The tech platform improves planning for serious illness treatment and end-of-life care using a cloud-based advance care planning, or ACP, platform that pairs with in-house support. Essentially, it allows patients to do their planning ahead and make sure that their wishes are actually put into action. According to Koda Health, this results in an average of $9,500 saved per-patient, as well as improved health outcomes.

"If we’re looking at speed of market adoption, it’s clear that Koda Health is at the forefront of a crucial transformation in Advance Care Planning," says Tatiana Fofanova, PhD, CEO of Koda Health, in a press release. “In just a few years, we’ve built out a product that now serves well over 700,000 patients nationwide for industry giants like Cigna, Privia and Houston Methodist.”

Dr. Desh Mohan, the chief medical officer for Koda Health says that it was important to the company to create strategic partnerships with its investors. In fact, Memorial Hermann isn’t just helping with funding. The hospital system is also collaborating with Koda on a new pilot project.

“Koda is uniquely positioned to serve payers, providers and patients,” adds William McKeon, president and CEO of Texas Medical Center. “We rarely see a company that provides value to all three stakeholders. Seeing Koda launch from our TMCi BioDesign program to the progress they've made with our member institutions and players in the value chain is incredible.”

Beyond the TMC, Koda’s collaboration with AARP goes through the latter’s AgeTech Collaborative. That ecosystem unites founders in the realm of longevity tech to make meaningful change in their field.

"AARP research shows that there is a willingness among older adults in the U.S. to prepare for the end of their lives," says Amelia Hay, VP of Startup Programming and Investments at AgeTech Collaborative. "This indicates a need for more programs and services geared towards ensuring adults take the necessary steps, and AARP is pleased to invest in Koda Health to help address that need."

Koda raised its first seed funding in 2022, a round that totaled $3.5 million. The new round close means that Koda can accelerate its efforts to modernize ACP.

Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the new space. Photo via houstonmethodist.org

Houston Methodist signs on at new TMC Helix Park building

moving in

Texas medical giant Houston Methodist is the latest to join the Dynamic One building within TMC Helix Park.

The hospital announced that it has signed a 75,800-square-foot lease in the building and will take over two floors of biomedical research laboratories. Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the space.

“We are always focused on translating innovative medical discoveries into viable therapies for patients. These highly entrepreneurial programs, which translate these discoveries to the bedside, are a natural fit within the emerging biotechnology ecosystem that the TMC is cultivating,” Edward Jones, president and CEO of Houston Methodist Research Institute, said in the announcement.

Houston Methodist joins anchor tenant Baylor College of Medicine in the state-of-the-art building, which opened in Nov. 2023.

The 12-story Dynamic One building features lab space, offices, restaurants, and stores. It represents the first of four buildings planned for the 37-acre TMC Helix Park and was one of the largest life sciences projects in the U.S. set to come online last year.

Developers are slated to open three more move-in-ready Beacon Ready Labs in the building this summer, ranging from 9,000 to 15,000 square feet.

“We are excited to welcome Houston Methodist to this space; their commitment to bench to bedside innovation and track record of transformative new discoveries aligns with our vision for the campus,” William McKeon, president and CEO of the Texas Medical Center, said in a statement. “Beacon Capital has been an outstanding partner in the development of TMC Helix Park, lending their insights to our efforts to design a campus that would seamlessly blend institutions and industry.”

TMC Helix Park officially opened last October with the launch of the TMC3 Collaborative Building. The 250,000-square-foot building anchors the campus and houses research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

UTHealth Houston also broke ground on its 350,000-square-foot tower on the campus last summer. It's slated to open in time for the 2026 Fall semester. And TMC unveiled plans for the fourth and final component of Helix Park, the TMC BioPort, in 2022.

This week's roundup of Houston innovators includes Nick Skytland of NASA, Neal Dikeman of Energy Transition Ventures, and Bill McKeon of TMC. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space tech to health care innovation — recently making headlines in Houston innovation.

Nick Skytland, chief technologist at NASA Johnson Space Center

Nick Skytland, chief technologist at NASA Johnson Space Center, joins the Houston Innovators Podcast. Photo via LinkedIn

For most people, it might be pretty hard to envision a future where astronauts are living on the moon or even Mars in the next few decades, but Nick Skytland, chief technologist at NASA Johnson Space Center, says he sees that future pretty clearly.

Since its inception in 1958, NASA has achieved many milestones, from the from putting the first man in orbit to having astronauts live in space for over 20 years consecutively. But it's a new era for NASA — and its commercial partners.

"What has changed in the past decade or so is that space flight is no longer just a government focus," Skytland says on the Houston Innovators Podcast. "We have an entire space industry that's growing and starting to thrive in the United States, and that's an important part of our strategy going forward." Read more.

Neal Dikeman, partner at Energy Transition Ventures

Houston-based energy tech investor Neal Dikeman writes his observations on Houston's venture capital and startup community's growth — in stark comparison of Silicon Valley's recent evolution. Photo via LinkedIn

In his guest column for InnovationMap, Neal Dikeman, a Houston-based energy transition investor, shares how Houston's innovation ecosystem differs from Silicon Valley these days. While deemed a newer ecosystem, there appears to be a growing amount of activity in and around the Ion, where Dikeman works out of. Meanwhile, Silicon Valley is pretty quiet.

"Founders are learning that Houston’s venture investment and tech scene has an actual home these days, and is open for business," he writes in the column. Read more.

Bill McKeon, CEO of the Texas Medical Center

Mayor Sylvester Turner, TMC CEO Bill McKeon, Governor Greg Abbott, and others gave their remarks at the TMC3 Collaborative Building opening. Photo via tmc.edu

For nearly a decade, thee Texas Medical Center and its partners have been working on the plans for Helix Park, a 37-acre campus expansion of TMC. As of this week, the first building has opened its doors to the public.

The TMC3 Collaborative Building officially opened today to a crowd of media, public officials, and health care executives. The institutional agnostic, 250,000-square-foot building will anchor Helix Park and house research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

“Today, we lay the cornerstone of a new campus fully dedicated to streamlining the commercialization of life-changing innovations in medicine and technologies,” William McKeon, president and CEO of TMC, says at the event. “We are incredibly excited to both welcome our founding institutions and industry partners to the Collaborative Building and to invite the community to experience the Helix Park campus and its beautiful parks with a series of special events in the months ahead." Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston energy trailblazer Fervo closes $462 million Series E

Fresh Funds

Houston-based geothermal energy company Fervo Energy has closed an oversubscribed $462 million series E funding round, led by new investor B Capital.

“Fervo is setting the pace for the next era of clean, affordable, and reliable power in the U.S.,” Jeff Johnson, general partner at B Capital, said in a news release.

“With surging demand from AI and electrification, the grid urgently needs scalable, always-on solutions, and we believe enhanced geothermal energy is uniquely positioned to deliver. We’re proud to support a team with the technical leadership, commercial traction, and leading execution capabilities to bring the world’s largest next-generation geothermal project online and make 24/7 carbon-free power a reality.”

The financing reflects “strong market confidence in Fervo’s opportunity to make geothermal energy a cornerstone of the 24/7 carbon-free power future,” according to the company. The round also included participation from Google, a longtime Fervo Partner, and other new and returning investors like Devon Energy, Mitsui & Co., Ltd., Mitsubishi Heavy Industries and Centaurus Capital. Centaurus Capital also recently committed $75 million in preferred equity to support the construction of Cape Station Phase I, Fervo noted in the release.

The latest funding will support the continued buildout of Fervo’s Utah-based Cape Station development, which is slated to start delivering 100 MW of clean power to the grid beginning in 2026. Cape Station is expected to be the world's largest next-generation geothermal development, according to Fervo. The development of several other projects will also be included in the new round of funding.

“This funding sharpens our path from breakthrough technology to large-scale deployment at Cape Station and beyond,” Tim Latimer, CEO and co-founder of Fervo, added in the news release. “We’re building the clean, firm power fleet the next decade requires, and we’re doing it now.”

Fervo recently won Scaleup of the Year at the 2025 Houston Innovation Awards, and previously raised $205.6 million in capital to help finance the Cape Station earlier this year. The company fully contracted the project's capacity with the addition of a major power purchase agreement from Shell this spring. Fervo’s valuation has been estimated at $1.4 billion and includes investments and support from Bill Gates.

“This new investment makes one thing clear: the time for geothermal is now,” Latimer added in a LinkedIn post. “The world desperately needs new power sources, and with geothermal, that power is clean and reliable. We are ready to meet the moment, and thrilled to have so many great partners on board.”

---

This article originally appeared on EnergyCapitalHTX.com.

Baylor center receives $10M NIH grant to continue rare disease research

NIH funding

Baylor College of Medicine’s Center for Precision Medicine Models received a $10 million, five-year grant from the National Institutes of Health last month that will allow it to continue its work studying rare genetic diseases.

The Center for Precision Medicine Models creates customized cell, fly and mouse models that mimic specific genetic variations found in patients, helping scientists to better understand how genetic changes cause disease and explore potential treatments.

The center was originally funded by an NIH grant, and its models have contributed to the discovery of several new rare disease genes and new symptoms caused by known disease genes. It hosts an online portal that allows physicians, families and advocacy groups to nominate genetic variants or rare diseases that need further investigation or new treatments.

Since its founding in 2020, it has received 156 disease/variant nominations, accepted 63 for modeling and produced more than 200 precision models, according to Baylor.

The center plans to use the latest round of funding to bring together more experts in rare disease research, animal modeling and bioinformatics, and to expand its focus and model more complex diseases.

Dr. Jason Heaney, associate professor in the Department of Molecular and Human Genetics at BCM, serves as the lead principal investigator of the center.

“The Department of Molecular and Human Genetics is uniquely equipped to bring together the diverse expertise needed to connect clinical human genetics, animal research and advanced bioinformatics tools,” Heaney added in the release. “This integration allows us to drive personalized medicine forward using precision animal models and to turn those discoveries into better care for patients.”

Houston institutions launch Project Metis to position region as global leader in brain health

brain trust

Leaders in Houston's health care and innovation sectors have joined the Center for Houston’s Future to launch an initiative that aims to make the Greater Houston Area "the global leader of brain health."

The multi-year Project Metis, named after the Greek goddess of wisdom and deep thought, will be led by the newly formed Rice Brain Institute, The University of Texas Medical Branch's Moody Brain Health Institute and Memorial Hermann’s comprehensive neurology care department. The initiative comes on the heels of Texas voters overwhelmingly approving a ballot measure to launch the $3 billion, state-funded Dementia Prevention and Research Institute of Texas (DPRIT).

According to organizers, initial plans for Project Metis include:

  • Creating working teams focused on brain health across all life stages, science and medical advances, and innovation and commercialization
  • Developing a regional Brain Health Index to track progress and equity
  • Implanting pilot projects in areas such as clinical care, education and workplace wellness
  • Sharing Houston’s progress and learnings at major international forums, including Davos and the UN General Assembly

The initiative will be chaired by:

  • Founding Chair: Dr. Jochen Reiser, President of UTMB and CEO of the UTMB Health System
  • Project Chair: Amy Dittmar, Howard R. Hughes Provost and Executive Vice President of Rice University
  • Project Chair: Dr. David L. Callender, President and CEO of Memorial Hermann Health System

The leaders will work with David Gow, Center for Houston’s Future president and CEO. Gow is the founder and chairman of Gow Media, InnovationMap's parent company.

“Now is exactly the right time for Project Metis and the Houston-Galveston Region is exactly the right place,” Gow said in a news release. “Texas voters, by approving the state-funded Dementia Prevention Institute, have shown a strong commitment to brain health, as scientific advances continue daily. The initiative aims to harness the Houston’s regions unique strengths: its concentration of leading medical and academic institutions, a vibrant innovation ecosystem, and a history of entrepreneurial leadership in health and life sciences.”

Lime Rock Resources, BP and The University of Texas MD Anderson Cancer Center served as early steering members for Project Metis. HKS, Houston Methodist and the American Psychiatric Association Foundation have also supported the project.

An estimated 460,000 Texans are living with dementia, according to the Alzheimer’s Association, and more than one million caregivers support them.

“Through our work, we see both the immense human toll of brain-related illness and the tremendous potential of early intervention, coordinated care and long-term prevention," Callender added in the release. "That’s why this bold new initiative matters so much."

View All Listings